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FLUOXETINE AND VASCULAR HEADACHES 
Headaches are a common adverse effect of fluoxetine therapy. A patient who developed vascular 
headaches while being treated for depression is reported and possible mechanisms discussed. 
Headache is described as a frequent adverse ef-
fect of fluoxetine, occurring in about 20% of patients 
receiving the drug (Wernicke, 1985). The occur-
rence of headaches during therapy is also a common 
theme in patients receiving other selective serotonin 
reuptake blockers (SSRIs) (Rickels & Schweizer, 
1990). What is, however, not clear from literature is 
the type of headaches that develop - consider, for 
example, that in clinical practice, the commonest 
types of headaches encountered are tension 
headache and vascular headaches. A case report is 
hence presented here to describe the association of 
vascular headaches with fluoxetine therapy. 
CASE REPORT 
Ms. M, 27, presented with a 4 month history of 
depression, weeping spells, decreased libido, insom-
nia with early morning awakening, decreased ap-
petite, loss of weight and psychomotor retardation. 
She fulfilled DSM III-R criteria for Major Depres-
sion with melancholia. She was started on 
fluoxetine, 20 mg each morning. By the end of two 
weeks she reported slight improvement in the 
severity of her depression. She continued to improve 
steadily and, after the second month of therapy, 
achieved remission from all symptoms. Fluoxetine 
was continued for 6 months further and was then 
tapered off and discontinued. 
Within the second week of therapy itself she 
began to report a new symptom - headaches. With 
progress of fluoxetine therapy, the headaches in-
creased in frequency, duration and severity. The 
headaches occurred four to five times a week and 
were characteristically bilateral and throbbing in 
nature. There was associated nausea and intolerance 
to light, but no preceding aura or warning of any sort. 
There was no history of such headaches at any time 
in the past. 
The headaches, clearly vascular in origin, were 
treated with propranolol in the dose of 20 mg twice 
daily. Propranolol was stepped up over two weeks 
to 40 mg thrice a day. At this dose, headaches 
decreased in frequency to about once a fortnight. 
Propranolol was continued for the duration of 
fluoxetine therapy and was tapered off and 
withdrawn along with the fluoxetine. One year later, 
the patient remains free from both depression and 
vascular headaches. She requires no medication for 
either complaint. 
DISCUSSION 
The SSRIs facilitate serotonergic neurotransmis-
sion. Enhanced serotonergicity has been suggested 
as one explanation for vascular headaches (Raskin, 
1988). This may explain the association between 
vascular headaches and fluoxetine therapy as ob-
served in the case above. Curiously, fluoxetine has 
also been used in the prophylaxis of migraine (Ras-
kin, 1988). Until the aetiology of vascular headaches 
and the role of serotonergic neurotransmission 
therein is better understood, it is futile to speculate 
on the possible mechanisms of balance that 
fluoxetine maintains or disturbs in preventing or 
precipitating headaches; however, the possibility of 
such an adverse effect of SSRIs must hence be kept 
in mind, particularly when treating a patient with a 
prior history of vascular headaches. 
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